# Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

> **NCT00777114** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 31 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** bortezomib, tositumomab

## Key facts

- **NCT ID:** NCT00777114
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-01
- **Primary completion:** 2012-12-18
- **Final completion:** 2012-12-18
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-08-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777114, "Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00777114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*